Literature DB >> 23715164

Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service.

Whitney M Green1, Raluca Yonescu, Laura Morsberger, Kerry Morris, George J Netto, Jonathan I Epstein, Peter B Illei, Mohamad Allaf, Marc Ladanyi, Constance A Griffin, Pedram Argani.   

Abstract

Xp11 translocation renal cell carcinomas (RCCs) are characterized by chromosome translocations involving the Xp11.2 breakpoint, resulting in gene fusions involving the TFE3 transcription factor. In archival material, the diagnosis can often be confirmed by TFE3 immunohistochemistry (IHC), but variable fixation (especially prevalent in consultation material) can lead to equivocal results. A TFE3 break-apart fluorescence in situ hybridization (FISH) assay has been developed to detect TFE3 gene rearrangements; however, the utility of this assay in a renal tumor consultation practice has not been examined. We reviewed 95 consecutive renal tumor consultation cases submitted to rule in or rule out Xp11 translocation RCC. Thirty-one cases were positive for TFE3 rearrangements by FISH. Patients ranged from 6 to 67 years of age (mean=30 y; median=28 y). Novel or distinctive morphologic features of these cases included extensive cystic change simulating multilocular cystic RCC (3 cases), sarcomatoid transformation (3 cases), oncocytic areas mimicking oncocytoma (1 case), trabecular architecture mimicking a carcinoid tumor (1 case), colonization of renal pelvic urothelium mimicking urothelial carcinoma in situ (1), and focal desmin and diffuse racemase immunoreactivity (1 case each). Twenty-six of the 31 TFE3 FISH-positive RCCs were unequivocally positive for TFE3 by IHC, but 4 were equivocal, and 1 was negative. Of the 64 cases that were negative by TFE3 FISH, 50 were negative by TFE3 IHC, and 14 were equivocal. Thirty-two of the 64 TFE3 FISH-negative cases could be classified into other accepted RCC subtypes: 23 as clear cell RCC, 5 as papillary RCC, 3 as clear cell papillary RCC, and 1 as chromophobe RCC. The other 32 cases remained unclassified, including 3 cathepsin K-positive RCC that closely resembled Xp11 translocation RCC. In conclusion, TFE3 FISH is highly useful in renal tumor consultation material, often resolving cases with equivocal TFE3 IHC results. Given the difficulty of optimizing TFE3 IHC, TFE3 FISH is for most laboratories the optimal test for establishing the diagnosis of Xp11 translocation RCC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23715164     DOI: 10.1097/PAS.0b013e31828a69ae

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  57 in total

Review 1.  Diagnostic approach to eosinophilic renal neoplasms.

Authors:  Oleksandr N Kryvenko; Merce Jorda; Pedram Argani; Jonathan I Epstein
Journal:  Arch Pathol Lab Med       Date:  2014-11       Impact factor: 5.534

2.  Clear cell papillary renal cell carcinoma and renal angiomyoadenomatous tumor: two variants of a morphologic, immunohistochemical, and genetic distinct entity of renal cell carcinoma.

Authors:  Karl-Friedrich Deml; Hans-Ulrich Schildhaus; Eva Compérat; Adriana von Teichman; Martina Storz; Peter Schraml; Joseph V Bonventre; Falko Fend; Barbara Fleige; Andreas Nerlich; Helmut E Gabbert; Nikolaus GaBler; Rainer Grobholz; Seife Hailemariam; Raoul Hinze; Ruth Knüchel; Benoit Lhermitte; Gabriella Nesi; Thomas Rüdiger; Guido Sauter; Holger Moch
Journal:  Am J Surg Pathol       Date:  2015-07       Impact factor: 6.394

Review 3.  MiT family translocation renal cell carcinomas: A 15th anniversary update.

Authors:  Jatin S Gandhi; Faizan Malik; Mahul B Amin; Pedram Argani; Armita Bahrami
Journal:  Histol Histopathol       Date:  2019-09-06       Impact factor: 2.303

4.  Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays.

Authors:  Stephanie L Skala; Hong Xiao; Aaron M Udager; Saravana M Dhanasekaran; Sudhanshu Shukla; Yang Zhang; Carrie Landau; Lina Shao; Diane Roulston; Lisha Wang; Javed Siddiqui; Xuhong Cao; Cristina Magi-Galluzzi; Miao Zhang; Adeboye O Osunkoya; Steven C Smith; Jesse K McKenney; Bryan L Betz; Jeffrey L Myers; Arul M Chinnaiyan; Scott A Tomlins; Rohit Mehra
Journal:  Mod Pathol       Date:  2017-08-25       Impact factor: 7.842

5.  Identification of molecular tumor markers in renal cell carcinomas with TFE3 protein expression by RNA sequencing.

Authors:  Dorothee Pflueger; Andrea Sboner; Martina Storz; Jasmine Roth; Eva Compérat; Elisabeth Bruder; Mark A Rubin; Peter Schraml; Holger Moch
Journal:  Neoplasia       Date:  2013-11       Impact factor: 5.715

6.  Do significant TFE3 gene rearrangements occur in succinate dehydrogenase-deficient renal cell carcinoma? Borderline FISH results should be interpreted with caution.

Authors:  Angela Chou; Ondrej Hes; John Turchini; Kiril Trpkov; Anthony J Gill
Journal:  Mod Pathol       Date:  2017-10       Impact factor: 7.842

7.  Reply to Chou et al 'Do significant TFE3 gene rearrangements occur in succinate dehydrogenase deficient renal cell carcinoma? Borderline FISH results should be interpreted with caution' Mod Pathol 2017; in press.

Authors:  Sean R Williamson; David J Grignon; Anna Calió; Bradley A Stohr; John N Eble; Liang Cheng
Journal:  Mod Pathol       Date:  2017-10       Impact factor: 7.842

8.  Xp11.2 translocation renal cell carcinoma with TFE3 gene fusion: A case report.

Authors:  Xiang Pan; Jing Quan; Liwen Zhao; Wenhua Li; Benlin Wei; Shangqi Yang; Yongqing Lai
Journal:  Mol Clin Oncol       Date:  2017-11-13

Review 9.  [The translocation carcinoma: A pediatric renal tumor also in adults].

Authors:  E Bruder; H Moch
Journal:  Pathologe       Date:  2016-03       Impact factor: 1.011

10.  TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.

Authors:  Pedram Argani; Minghao Zhong; Victor E Reuter; John T Fallon; Jonathan I Epstein; George J Netto; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2016-06       Impact factor: 6.394

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.